118 related articles for article (PubMed ID: 15059321)
1. [Hypermethylation of p16 gene in clinical specimens of patients with lung cancer].
Liu JY; An Q; Xu GD; Lei WD; Li L; Pan QJ; Han NJ; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):75-7. PubMed ID: 15059321
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications.
Liu Y; An Q; Li L; Zhang D; Huang J; Feng X; Cheng S; Gao Y
Carcinogenesis; 2003 Dec; 24(12):1897-901. PubMed ID: 12970072
[TBL] [Abstract][Full Text] [Related]
3. [Detection of hypermethylation of p16 gene in plasma DNA from lung cancer patients].
Liu JY; An Q; Xu GD; Lei WD; Feng XL; Guo SP; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):154-7. PubMed ID: 15196435
[TBL] [Abstract][Full Text] [Related]
4. Highly sensitive determination of the methylated p16 gene in cancer patients by microchip electrophoresis.
Zhou XM; Shao SJ; Xu GD; Zhong RT; Liu DY; Tang JW; Gao YN; Cheng SJ; Lin BC
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):145-51. PubMed ID: 15664344
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
Hu XC; Wong IH; Chow LW
Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
8. Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: correlation with smoking.
Georgiou E; Valeri R; Tzimagiorgis G; Anzel J; Krikelis D; Tsilikas C; Sarikos G; Destouni C; Dimitriadou A; Kouidou S
Eur J Cancer Prev; 2007 Oct; 16(5):396-402. PubMed ID: 17923809
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung.
Awaya H; Takeshima Y; Amatya VJ; Furonaka O; Tagawa K; Kohno N; Inai K
Pathol Int; 2004 Jul; 54(7):486-9. PubMed ID: 15189501
[TBL] [Abstract][Full Text] [Related]
10. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.
Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J
Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607
[TBL] [Abstract][Full Text] [Related]
11. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
Grote HJ
Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
[TBL] [Abstract][Full Text] [Related]
12. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnostic markers for lung cancer in sputum and plasma.
Wang YC; Hsu HS; Chen TP; Chen JT
Ann N Y Acad Sci; 2006 Sep; 1075():179-84. PubMed ID: 17108209
[TBL] [Abstract][Full Text] [Related]
15. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers.
Destro A; Bianchi P; Alloisio M; Laghi L; Di Gioia S; Malesci A; Cariboni U; Gribaudi G; Bulfamante G; Marchetti A; Bosari S; Infante M; Ravasi G; Roncalli M
Lung Cancer; 2004 Apr; 44(1):23-32. PubMed ID: 15013580
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
17. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
Kim YT; Park SJ; Lee SH; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1378. PubMed ID: 16256792
[TBL] [Abstract][Full Text] [Related]
19. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile.
Guzman LM; Koriyama C; Akiba S; Eizuru Y; Castillo D; Corvalan A; Aguayo FR
Biol Res; 2007; 40(3):365-72. PubMed ID: 18449464
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
